Published in Oncogene on May 18, 2015
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | NCT02117479
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE) | NCT01458574
A Study of Ruxolitinib in Pancreatic Cancer Patients | NCT02119663
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours | NCT01112397
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | NCT02066532
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors | NCT00985868
Study of Ruxolitinib in Colorectal Cancer Patients | NCT02119676
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | NCT02119650
The Safety And Efficacy Of Maintenance Therapy With CP-690,550 | NCT01393899
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease | NCT02048618
Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition. J Exp Clin Cancer Res (2015) 0.93
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. Oncotarget (2016) 0.92
Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. Front Oncol (2016) 0.85
Leptin-Induced JAK/STAT Signaling and Cancer Growth. Vaccines (Basel) (2016) 0.82
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol (2016) 0.79
JAK-STAT in lymphoproliferative disorders. Oncoscience (2015) 0.78
Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling. Oncotarget (2016) 0.78
Smoking, inflammation and small cell lung cancer: recent developments. Wien Med Wochenschr (2015) 0.77
Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol (2016) 0.76
Modes of invasion during tumour dissemination. Mol Oncol (2016) 0.76
Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer. Vaccines (Basel) (2016) 0.75
Icariside II overcomes TRAIL resistance of melanoma cells through ROS-mediated downregulation of STAT3/cFLIP signaling. Oncotarget (2016) 0.75
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun (2016) 0.75
Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Sci Rep (2016) 0.75
Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells. PLoS Comput Biol (2016) 0.75
Nuclear Import of JAK1 is Mediated by a Classical NLS and is Required for Survival of Diffuse Large B-cell Lymphoma. Mol Cancer Res (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Stat3 as an oncogene. Cell (1999) 17.39
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 15.33
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun (1998) 7.86
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
A renaissance for SRC. Nat Rev Cancer (2004) 6.27
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 6.17
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 6.05
Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut. Cell (2009) 5.57
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
JAK-STAT signaling: from interferons to cytokines. J Biol Chem (2007) 5.28
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Function of mitochondrial Stat3 in cellular respiration. Science (2009) 5.13
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med (2009) 4.94
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med (2012) 4.85
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Signal transduction and the control of gene expression. Science (2002) 4.38
A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell (2014) 4.35
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Drosophila intestinal response to bacterial infection: activation of host defense and stem cell proliferation. Cell Host Microbe (2009) 4.21
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 3.99
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science (2009) 3.89
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (1996) 3.70
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A (2001) 3.29
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene (2009) 3.09
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest (1998) 3.01
Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol (2011) 2.80
Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol (1997) 2.71
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 2.69
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell (2011) 2.57
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene (2004) 2.52
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med (2013) 2.50
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol (1991) 2.47
ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem (1999) 2.41
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood (2005) 2.41
Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res (2002) 2.41
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol (2006) 2.30
IL-6 involvement in epithelial cancers. J Clin Invest (2007) 2.29
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia (2013) 2.25
The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity (2014) 2.22
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett (2002) 2.21
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res (2011) 2.08
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol (2011) 2.05
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity (2013) 2.01
Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol (2012) 1.99
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell (2014) 1.96
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene (1990) 1.95
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol (2014) 1.89
The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration. Development (2010) 1.89
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol (2002) 1.89
Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem (2003) 1.88
Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol (2007) 1.85
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A (1994) 1.84
JAK/STAT signaling coordinates stem cell proliferation and multilineage differentiation in the Drosophila intestinal stem cell lineage. Dev Biol (2009) 1.83
Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun (2015) 1.79
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res (2008) 1.78
EGF signaling regulates the proliferation of intestinal stem cells in Drosophila. Development (2011) 1.76